BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Pulmonary vascular resistance
研究概览
简要总结
Volume overload due to left-to-right shunting in patients with atrial septal defect type secundum causes pulmonary vascular disease over a long period of time. Pulmonary vascular resistance can be assessed non-invasively using bicycle stress echocardiography. By measuring cardiac output and pulmonary artery pressures at different stages of exercise, a pressure-output plot can be obtained. The slope of the pressure-output plot reflects pulmonary vascular resistance. In patients undergoing ASD repair after the age of 40 years, pulmonary vascular resistance was higher when compared to age-matched controls, indicating the presence of mild pulmonary vascular disease. Bosentan has been shown to decrease pulmonary vascular resistance.
The investigators hypothesize that in patients with an ASD type secundum, who underwent ASD repair after the age of 40 years, administration of bosentan decreases pulmonary vascular resistance as assessed by bicycle stress echocardiography.
详细描述
- INTRODUCTION AND RATIONALE
1.1 MEDICAL BACKGROUND
Atrial septal defect (ASD) represents approximately 10% of all congenital heart diseases and is the third most common form of congenital heart defect. The incidence of congenital heart disease in Belgium is 1%, with ASD accounting for 25% of the cases (Data from the database of congenital heart diseases UZ Leuven.) Characterized by a free communication between the left and the right atrium, it may take the form of an ostium secundum defect (in the region of the fossa ovalis); an ostium primum defect (in the lower part of the atrial septum and associated with mitral regurgitation) or a sinus venosus defect (in the upper atrial septum and associated with anomalous drainage of one or more pulmonary veins)
Patients with atrial septal defect (ASD) initially present with a left-to-right shunt, which may cause elevated pulmonary artery pressures at rest and/or during exercise. However, this persistently elevated pulmonary blood-flow also causes progressive lesions of the pulmonary vasculature, as first described by Heath and Edwards. The earlier stages present with medial hypertrophy and/or intimal proliferation and are largely reversible after closure of the defect. Later stages, however, are irriversible: the origin of pulmonary arterial hypertension (PAH). Eventually, this volume and pressure overload of the right heart may lead to heart failure and/or arrhythmias. As PVR exceeds systemic resistance, the shunt is reversed (right-to-left shunt) leading to systemic arterial desaturation (and the related consequences: polyglobulia, hyperuricemia, decreased renal function and abnormal coagulation): the Eisenmenger syndrome (ES). When occlusive fibrotic lesions have developed later in life, closure of the ASD, although still feasible, may not result in complete normalization of pulmonary artery pressures. Moreover, it has been shown that closure after the age of 40 years is associated with worse outcome. It has been suggested that an abnormal increase in pulmonary artery pressures during exercise reflects mild pulmonary vascular disease. However, pulmonary artery pressures are defined by both cardiac output and pulmonary vascular resistance. During exercise, the relationship between pulmonary artery pressures and cardiac output is slightly curvilinear because of a natural distensibility of the pulmonary arterioles. Using bicycle stress echocardiography, pulmonary vascular resistance can be estimated either as a ratio of pulmonary artery pressure and cardiac output at each stage (total PVR) or by using linear regression analysis of the pressure-flow plots (dynamic PVR).
Prognosis of patients with unrepaired ASDs is thought to be shortened and repair can avoid right ventricular (RV) failure, pulmonary hypertension, thrombo-embolic events and atrial dysrrhythmias. So, when the defect is discovered early, an ASD is usually closed in childhood, unless the defect is considered not to be clinical significant. Sometimes, as most patients with an isolated ASD are asymptomatic during childhood, an ASD comes to medical attention at an older age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent by patient prior to initiation of any study-mandated procedure.
- •Male or female patients > 40 years with atrial septal defect type secundum and > 40 years of age at the time of repair
- •Women of childbearing potential must have a negative pre-treatment pregnancy test and must use a reliable method of contraception during study treatment and for at least 3 months after study treatment termination.
- •Women not of childbearing potential are defined as postmenopausal (amenorrhea for at least 1 year), or documented surgically or naturally sterile.
排除标准
- •Pregnancy or lactation
- •Women of child-bearing age who are sexually active without practising reliable methods of contraception
- •Any disease or impairment that, in the opinion of the investigator, excludes a subject from participation
- •Substance abuse (alcohol, medicines, drugs)
- •Other medical, psychological or social circumstances that would adversely affect a patient's ability to participate adequately in the study or increase the risk to the patient or others in the case of participation
- •Insufficient compliance
- •Subjects who are not able to perform cardiopulmonary exercise testing
- •ASD repair < 6 months before inclusion
- •PAH of any aetiology other than the one specified in the inclusion criteria
- •Impairment of organic function (renal, hepatic)
- •Arterial hypotension (systolic blood pressure < 85 mmHg)
- •Anaemia (Hb< 10 g/dl)
- •Decompensated symptomatic polycythemia
- •Thrombocytopenia (< 50000/µl)
- •Significant valvular diseases, other than tricuspid or pulmonary regurgitation
- •Chronic lung disease or total lung capacity < 80% of predicted value
- •History of significant pulmonary embolism
- •Other relevant diseases (HIV infection, Hep B/C infection)
- •Subjects with known intolerance to bosentan or their constituents
- •Prohibited medication: any medication listed below which has not been discontinued at least 30 days prior to screening
- •Unspecified or other significant medication (glyburide or immunosuppression)
- •Drugs to treat PAH (endothelin receptor antagonists, PDE-5 antagonists, prostanoids)
- •Medication that is not compatible with bosentan or that interferes with its metabolism (inhibitors of CYP2C9 or CYP3A4) or that, in the investigator's opinion, may interfere with bosentan treatment.
研究组 & 干预措施
Active
干预措施: Bosentan (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Pulmonary vascular resistance
时间窗: 16 weeks
Pulmonary vascular resistance can be measured using bicycle stress echocardiography by estimating the slope of a pressure-flow plot using linear regression analysis.
次要结局
- Peak oxygen consumption(16 weeks)
- Right ventricular function(16 weeks)
- Liver function abnormalities(4, 8,12 and16 weeks)
研究者
Alexander Van De Bruaene
Dr
Universitaire Ziekenhuizen KU Leuven
